{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:14:16Z","timestamp":1788556456534,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,5,17]],"date-time":"2013-05-17T00:00:00Z","timestamp":1368748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,5,17]],"date-time":"2013-05-17T00:00:00Z","timestamp":1368748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1038\/ijo.2013.74","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T11:24:39Z","timestamp":1370431479000},"page":"292-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Addiction potential of phentermine prescribed during long-term treatment of obesity"],"prefix":"10.1038","volume":"38","author":[{"given":"E J","family":"Hendricks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Srisurapanont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S L","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Haggard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Souter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C L","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D G","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Istratiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F L","family":"Greenway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,17]]},"reference":[{"key":"BFijo201374_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.annepidem.2012.01.001","volume":"22","author":"NR Samaranayake","year":"2012","unstructured":"Samaranayake NR, Ong KL, Leung RY, Cheung BM . Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008. Ann Epidemiol 2012; 22: 349\u2013353.","journal-title":"Ann Epidemiol"},{"key":"BFijo201374_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-143-5-200509060-00013","volume":"143","author":"E Colman","year":"2005","unstructured":"Colman E . Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005; 143: 380\u2013385.","journal-title":"Ann Intern Med"},{"key":"BFijo201374_CR3","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/archinte.161.15.1814","volume":"161","author":"G Glazer","year":"2001","unstructured":"Glazer G . Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001; 161: 1814\u20131824.","journal-title":"Arch Intern Med"},{"key":"BFijo201374_CR4","doi-asserted-by":"publisher","first-page":"179674","DOI":"10.1155\/2011\/179674","volume":"2011","author":"LL Ioannides-Demos","year":"2011","unstructured":"Ioannides-Demos LL, Piccenna L, McNeil JJ . Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011; 2011: 179674.","journal-title":"J Obes"},{"key":"BFijo201374_CR5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","volume":"12","author":"JG Kang","year":"2010","unstructured":"Kang JG, Park CY, Kang JH, Park YW, Park SW . Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab 2010; 12: 876\u2013882.","journal-title":"Diabetes Obes Metab"},{"key":"BFijo201374_CR6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","volume":"47","author":"KK Kim","year":"2006","unstructured":"Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR . Effects on weight reduction and safety of short-term phentermine administration in korean obese people. Yonsei Med J 2006; 47: 614\u2013625.","journal-title":"Yonsei Med J"},{"key":"BFijo201374_CR7","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/oby.2004.226","volume":"12","author":"A Frank","year":"2004","unstructured":"Frank A . The long-term management of obesity with continuing pharmacotherapy. Obes Res 2004; 12: 1821\u20131827.","journal-title":"Obes Res"},{"key":"BFijo201374_CR8","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/oby.2011.94","volume":"19","author":"EJ Hendricks","year":"2011","unstructured":"Hendricks EJ, Greenway FL, Westman EC, Gupta AK . Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring) 2011; 19: 2351\u20132360.","journal-title":"Obesity (Silver Spring)"},{"key":"BFijo201374_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/MJT.0b013e31818e30da","volume":"17","author":"RB Rothman","year":"2010","unstructured":"Rothman RB . Treatment of obesity with \u2018combination\u2019 pharmacotherapy. Am J Ther 2010; 17: 596\u2013603.","journal-title":"Am J Ther"},{"key":"BFijo201374_CR10","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/oby.2009.69","volume":"17","author":"EJ Hendricks","year":"2009","unstructured":"Hendricks EJ, Rothman RB, Greenway FL . How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 2009; 17: 1730\u20131735.","journal-title":"Obesity (Silver Spring)"},{"key":"BFijo201374_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/MJT.0b013e3181d070d7","volume":"18","author":"EJ Hendricks","year":"2011","unstructured":"Hendricks EJ, Greenway FL . A study of abrupt phentermine cessation in patients in a weight management program. Am J Ther 2011; 18: 292\u2013299.","journal-title":"Am J Ther"},{"issue":"Suppl 20","key":"BFijo201374_CR12","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl 20): 22\u201333 quiz 34-57.","journal-title":"J Clin Psychiatry"},{"key":"BFijo201374_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1046\/j.1360-0443.1995.9056072.x","volume":"90","author":"M Gossop","year":"1995","unstructured":"Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995; 90: 607\u2013614.","journal-title":"Addiction"},{"key":"BFijo201374_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0376-8716(93)90042-O","volume":"34","author":"ST Tiffany","year":"1993","unstructured":"Tiffany ST, Singleton E, Haertzen CA, Henningfield JE . The development of a cocaine craving questionnaire. Drug Alcohol Depend 1993; 34: 19\u201328.","journal-title":"Drug Alcohol Depend"},{"key":"BFijo201374_CR15","unstructured":"McGregor C Amphetamine withdrawal:nature, time course, and treatment. PhD Thesis. Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, 2005, 224pp."},{"key":"BFijo201374_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1046\/j.1440-1614.1999.00517.x","volume":"33","author":"M Srisurapanont","year":"1999","unstructured":"Srisurapanont M, Jarusuraisin N, Jittiwutikan J . Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Aust N Z J Psychiatry 1999; 33: 89\u201393.","journal-title":"Aust N Z J Psychiatry"},{"key":"BFijo201374_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jsat.2006.05.009","volume":"31","author":"AJ Heinz","year":"2006","unstructured":"Heinz AJ, Epstein DH, Schroeder JR, Singleton EG, Heishman SJ, Preston KL . Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat 2006; 31: 355\u2013364.","journal-title":"J Subst Abuse Treat"},{"key":"BFijo201374_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000253550","volume":"60","author":"R Bruno","year":"2009","unstructured":"Bruno R, Matthews AJ, Topp L, Degenhardt L, Gomez R, Dunn M . Can the severity of dependence scale be usefully applied to \u2018ecstasy\u2019? Neuropsychobiology 2009; 60: 137\u2013147.","journal-title":"Neuropsychobiology"},{"key":"BFijo201374_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/j.1360-0443.1997.tb02953.x","volume":"92","author":"L Topp","year":"1997","unstructured":"Topp L, Mattick RP . Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 1997; 92: 839\u2013845.","journal-title":"Addiction"},{"key":"BFijo201374_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/j.1360-0443.2002.00121.x","volume":"97","author":"S Kaye","year":"2002","unstructured":"Kaye S, Darke S . Determining a diagnostic cut-off on the Severity of Dependence Scale (SDS) for cocaine dependence. Addiction 2002; 97: 727\u2013731.","journal-title":"Addiction"},{"key":"BFijo201374_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drugalcdep.2005.10.014","volume":"83","author":"G Martin","year":"2006","unstructured":"Martin G, Copeland J, Gates P, Gilmour S . The Severity of Dependence Scale (SDS) in an adolescent population of cannabis users: reliability, validity and diagnostic cut-off. Drug Alcohol Depend 2006; 83: 90\u201393.","journal-title":"Drug Alcohol Depend"},{"key":"BFijo201374_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2011.06298.x","volume":"1248","author":"ST Tiffany","year":"2012","unstructured":"Tiffany ST, Wray JM . The clinical significance of drug craving. Ann N Y Acad Sci 2012; 1248: 1\u201317.","journal-title":"Ann N Y Acad Sci"},{"key":"BFijo201374_CR23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/10550490902925920","volume":"18","author":"TF Newton","year":"2009","unstructured":"Newton TF, De La Garza R 2nd, Kalechstein AD, Tziortzis D, Jacobsen CA . Theories of addiction: methamphetamine users' explanations for continuing drug use and relapse. Am J Addict 2009; 18: 294\u2013300.","journal-title":"Am J Addict"},{"key":"BFijo201374_CR24","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/j.1360-0443.2005.01160.x","volume":"100","author":"C McGregor","year":"2005","unstructured":"McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM . The nature, time course and severity of methamphetamine withdrawal. Addiction 2005; 100: 1320\u20131329.","journal-title":"Addiction"},{"key":"BFijo201374_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/BF00404223","volume":"14","author":"JM van Rossum","year":"1969","unstructured":"van Rossum JM, Simons F . Locomotor activity and anorexogenic action. Psychopharmacologia 1969; 14: 248\u2013254.","journal-title":"Psychopharmacologia"},{"key":"BFijo201374_CR26","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.pnpbp.2011.01.014","volume":"35","author":"M Srisurapanont","year":"2011","unstructured":"Srisurapanont M, Arunpongpaisal S, Wada K, Marsden J, Ali R, Kongsakon R . Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 959\u2013964.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFijo201374_CR27","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1503\/cmaj.071675","volume":"178","author":"SJ Kish","year":"2008","unstructured":"Kish SJ . Pharmacologic mechanisms of crystal meth. CMAJ 2008; 178: 1679\u20131682.","journal-title":"CMAJ"},{"key":"BFijo201374_CR28","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/j.1360-0443.2010.03066.x","volume":"105","author":"T Zorick","year":"2010","unstructured":"Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 2010; 105: 1809\u20131818.","journal-title":"Addiction"},{"key":"BFijo201374_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0893-133X(95)00113-R","volume":"14","author":"LH Brauer","year":"1996","unstructured":"Brauer LH, Johanson CE, Schuster CR, Rothman RB, de Wit H . Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers. Neuropsychopharmacology 1996; 14: 233\u2013241.","journal-title":"Neuropsychopharmacology"},{"key":"BFijo201374_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.drugalcdep.2008.01.008","volume":"95","author":"DR Jasinski","year":"2008","unstructured":"Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ . Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008; 95: 140\u2013146.","journal-title":"Drug Alcohol Depend"},{"key":"BFijo201374_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/JCP.0b013e31825d380d","volume":"32","author":"KA Schoedel","year":"2012","unstructured":"Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A et al. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. J Clin Psychopharmacol 2012; 32: 492\u2013502.","journal-title":"J Clin Psychopharmacol"},{"key":"BFijo201374_CR32","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1520\/JFS15296J","volume":"47","author":"FJ Couper","year":"2002","unstructured":"Couper FJ, Pemberton M, Jarvis A, Hughes M, Logan BK . Prevalence of drug use in commercial tractor-trailer drivers. J Forensic Sci 2002; 47: 562\u2013567.","journal-title":"J Forensic Sci"},{"key":"BFijo201374_CR33","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.forsciint.2010.11.004","volume":"207","author":"S Lee","year":"2011","unstructured":"Lee S, Kim J, In S, Choi H, Chung H, Chung KH . Detection of phentermine in hair samples from drug suspects. Forensic Sci Int 2011; 207: e5\u2013e7.","journal-title":"Forensic Sci Int"},{"key":"BFijo201374_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/00952997909007032","volume":"6","author":"NC Jain","year":"1979","unstructured":"Jain NC, Budd RD, Sneath TC . Frequency of use or abuse of amphetamine-related drugs. Am J Drug Alcohol Abuse 1979; 6: 53\u201357.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"BFijo201374_CR35","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.2174\/138161211795656846","volume":"17","author":"WM Greene","year":"2011","unstructured":"Greene WM, Sylvester M, Abraham J . Addiction liability of pharmacotherapeutic interventions in obesity. Curr Pharm Des 2011; 17: 1188\u20131192.","journal-title":"Curr Pharm Des"},{"key":"BFijo201374_CR36","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th edn American Psychiatric Association: Washington, DC, USA, 2000."},{"key":"BFijo201374_CR37","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1176\/ajp.2006.163.5.764","volume":"163","author":"CP O'Brien","year":"2006","unstructured":"O'Brien CP, Volkow N, Li TK . What's in a word? Addiction versus dependence in DSM-V. Am J Psychiatry 2006; 163: 764\u2013765.","journal-title":"Am J Psychiatry"},{"key":"BFijo201374_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0306-4603(98)00011-2","volume":"23","author":"KM Kampman","year":"1998","unstructured":"Kampman KM, Volpicelli JR, McGinnis DE, Alterman AI, Weinrieb RM, D'Angelo L et al. Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav 1998; 23: 449\u2013461.","journal-title":"Addict Behav"},{"key":"BFijo201374_CR39","doi-asserted-by":"publisher","unstructured":"Shoptaw SJ, Kao U, Heinzerling K, Ling W . Treatment for amphetamine withdrawal. Cochrane Database Syst Rev 2009; CD003021 doi: 10.1002\/14651858.","DOI":"10.1002\/14651858"},{"key":"BFijo201374_CR40","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/10550490600998476","volume":"15","author":"J Ahmadi","year":"2006","unstructured":"Ahmadi J, Kampman K, Dackis C . Outcome predictors in cocaine dependence treatment trials. Am J Addict 2006; 15: 434\u2013439.","journal-title":"Am J Addict"},{"key":"BFijo201374_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/10550490802545174","volume":"18","author":"J Ahmadi","year":"2009","unstructured":"Ahmadi J, Kampman KM, Oslin DM, Pettinati HM, Dackis C, Sparkman T . Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. Am J Addict 2009; 18: 81\u201386.","journal-title":"Am J Addict"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ijo201374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijo201374","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijo201374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T19:07:35Z","timestamp":1647371255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijo201374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,17]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["BFijo201374"],"URL":"https:\/\/doi.org\/10.1038\/ijo.2013.74","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,17]]},"assertion":[{"value":"11 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Hendricks has received honoraria from Akramax Pharmaceuticals, Eurodrug Laboratories, Citius Pharmaceuticals and Vivus pharmaceuticals. Dr Greenway has received honoraria from Baronova, Basic Research, Citius, Diabetic Living, Eisai, GNC, Jenny Craig, Lithera, Merck, Naturalpha, Nume Health, Orexigen, Plensat, Takeda, Thetis, Unigene and Zafgen. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}